Last reviewed · How we verify
Hybrid regimen
Hybrid regimen is a Small molecule drug developed by Ayman Magd Eldin Mohammad Sadek. It is currently FDA-approved.
A hybrid regimen is a treatment approach that combines different interventions, including indomethacin suppository and N-acetylcysteine (NAC), to prevent or treat various conditions such as post-ERCP pancreatitis, HIV infections, rectal cancer, and colorectal cancer. This regimen is considered a small molecule modality, as indicated by its classification in the ChEMBL database.
At a glance
| Generic name | Hybrid regimen |
|---|---|
| Sponsor | Ayman Magd Eldin Mohammad Sadek |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy (PHASE3)
- Two Way Crossover Closed Loop MPC vs Control IQ (NA)
- This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R (NA)
- Mirror Therapy and Augmented Reality in Stroke Rehabilitation (NA)
- Digital Physiotherapy for Pediatric Chronic Suppurative Lung Diseases (NA)
- A Prospective Randomised Study of Treatment Selection Based on Epigenetic Markers Versus Standard of Care Treatment Selection in Adults With CROHN's Disease (NA)
- The Impact of PReOPerative Exercise and NutritionaL Optimization on Perioperative Outcomes for Patients Undergoing Treatment for Rectal Cancer: The PROPEL Trial (NA)
- The Video-Based Exercise Programs in Degenerative Meniscus Tears (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hybrid regimen CI brief — competitive landscape report
- Hybrid regimen updates RSS · CI watch RSS
- Ayman Magd Eldin Mohammad Sadek portfolio CI
Frequently asked questions about Hybrid regimen
What is Hybrid regimen?
Who makes Hybrid regimen?
What development phase is Hybrid regimen in?
Related
- Manufacturer: Ayman Magd Eldin Mohammad Sadek — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing